Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia (CurcumPedALL)
Acute Lymphoblastic Leukemia, Pediatric
About this trial
This is an interventional supportive care trial for Acute Lymphoblastic Leukemia, Pediatric focused on measuring Curcumin, Ain Shams University, Egypt, Acute Lymphoblastic Leukemia, Children
Eligibility Criteria
Inclusion Criteria:
Children aged from 1 year to 18 years Children with proven ALL diagnosed by bone marrow aspirate and immunephenotyping Patients in the maintenance phase week1
Exclusion Criteria:
Children with other maliganacies, Current use (past use of these medications is not an exclusion) of medications or over-the-counter treatments including to sulfasalazine, warfarin, clopidogrel, aspirin, antacids, botanical treatments (ginger, feverfew, yellow clover, Salix species, Populus species, Betula species, and Gaultheria species), essential fatty acids (flax oil and fish oil).
Sites / Locations
- Pediatric Hematology Oncology and BMT Unit, Faculty of Medicine Ain Shams UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Curcumin
Standard of nutritional care
Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement (composed of Tumeric (curcuma longa)root 450mg and Tumeric extract (curcuma longa )root 50mg ) standardized to contain 95%curcuminoids, it will given twice daily for 1 month starting at week 1 of maintenance phase of chemotherapy (Time 1) . It is preferably to be taken with meals but may be opened and prepared as a tea
Standard of nutritional support care